Literature DB >> 15186254

Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies.

Stuart P Berzins1, Kon Kyparissoudis, Daniel G Pellicci, Kristen J Hammond, Stephane Sidobre, Alan Baxter, Mark J Smyth, Mitchell Kronenberg, Dale I Godfrey.   

Abstract

In the diabetes-prone NOD mouse, there is a proven association between a systemic deficiency of NKT cells and the onset of type 1 diabetes. Numerous reports of similar defects within the NKT cell compartment of human type 1 diabetes patients suggested NKT cell levels might be a valuable predictor of susceptibility and could provide a target for therapeutic intervention. Two recent studies, however, found no association between type 1 diabetes and blood NKT cell levels in humans and consequently rejected a link between the onset of diabetes and NKT cell deficiency. This cast considerable doubts on the potential for NKT cell-based clinical applications and challenged the validity of the NOD mouse as a model of human type 1 diabetes. We now report that NKT cell levels in blood are a poor representation of those in other organs. Strikingly, systemic NKT cell deficiencies were identified in NOD mice with normal, or even raised, blood levels. This re-establishes the correlation between NKT cell deficiency and type 1 diabetes and raises important questions regarding the assaying of NKT cell levels in humans.

Entities:  

Mesh:

Year:  2004        PMID: 15186254     DOI: 10.1046/j.1440-1711.2004.01238.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  20 in total

1.  Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type.

Authors:  Y-G Chen; S-W Tsaih; D V Serreze
Journal:  Genes Immun       Date:  2011-09-22       Impact factor: 2.676

Review 2.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  Type 1 diabetes and NKT cells: a report on the 3rd International Workshop on NKT cells and CD1-mediated antigen presentation, September 2004, Heron Island, QLD, Australia.

Authors:  Julie M Fletcher; Margaret A Jordan; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2004-11-10

Review 4.  The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.

Authors:  S L Cardell
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 5.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

Review 6.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

7.  Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets.

Authors:  A C Chan; E Leeansyah; A Cochrane; Y d'Udekem d'Acoz; D Mittag; L C Harrison; D I Godfrey; S P Berzins
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

8.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

9.  Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders.

Authors:  E Zigmond; S Preston; O Pappo; G Lalazar; M Margalit; Z Shalev; L Zolotarov; D Friedman; R Alper; Y Ilan
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 10.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.